Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 721

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 3
Chunk 721
---
 outstanding 
     —  
     — 
  
    Common stock, $0.00001 par value; 100,000,000 shares authorized; 4,076,567 shares issued and outstanding at December 31, 2024; 2,008,689 shares issued and outstanding at December 31, 2023 
     41  
     20 
  
    Additional paid in capital 
     35,287,212  
     29,489,055 
  
    Accumulated deficit 
     (34,578,101) 
     (25,433,304)
  
    Total Stockholders’ Equity 
     709,152  
     4,055,771 
  
    Total Liabilities and Stockholders’ Equity 
    $2,506,290  
    $5,951,736 

The
accompanying notes are an integral part of these consolidated financial statements.

F-2

Shuttle
Pharmaceuticals Holdings, Inc.

Consolidated
Statements of Operations

    2024  
    2023 

    Years Ended December 31, 

    2024  
    2023 

    Revenue 
    $—  
     — 

    Operating expenses 

    Research and development, net of contract expense reimbursements 
     3,618,796  
     3,517,093 
  
    General and administrative 
     1,392,709  
     1,046,854 
  
    Legal and professional 
     2,684,665  
     1,328,435 
  
    Total operating expenses 
     7,696,170  
     5,892,382 

    Net loss from operations 
     (7,696,170) 
     (5,892,382)

    Other income (expense) 

    Interest expense - related parties 
     (8,692) 
     (6,825)
  
    Interest expense 
     (1,198,738) 
     (2,484,193)
  
    Interest income 
     38,138  
     79,117 
  
    Convertible notes finance fee 
     (152,726) 
     (104,245)
  
    Change in fair value of derivative liabilities 
     555,789  
     2,216